Effect of diabetes mellitus on association between galectin-3 and H2FPEF score in patients with unexplained dyspnea and a preserved left ventricular ejection fraction

dc.contributor.authorDogdu, Orhan
dc.contributor.authorKarasu, Mehdi
dc.contributor.authorKaraca, Yuecel
dc.contributor.authorHarman, Murat
dc.date.accessioned2026-08-12T17:21:03Z
dc.date.issued2023
dc.departmentFırat Üniversitesi
dc.description.abstractObjectivesThe aim of this study was to investigate the effect of diabetes mellitus (DM) on the association between Galectin-3 (Gal-3) and the H2FPEF score in patients with unexplained dyspnea and a preserved left ventricular ejection fraction (LVEF).MethodsA cross-sectional observational study was conducted on patients with unexplained dyspnea and a preserved LVEF in the Cardiology Department of Elazig Medical Park Hospital, Turkey. The patients were evaluated based on the presence of DM and the H2FPEF score. Gal-3 levels were compared between groups, and the effect of DM on Gal-3 was assessed. The level of statistical significance in all tests was set at p < .05.ResultsGal-3 and H2FPEF scores were higher in patients with DM (p < .001 and p = .027, respectively). Gal-3 and HbA1C values were elevated in patients with moderate to high H2FPEF scores (p < .01 and p = .036, respectively). DM and Hypertension were more prevalent in patients with moderate to high H2FPEF scores (p = 0.024, p < 0.001, respectively). A strong correlation was observed between Gal-3 and the H2FPEF score (r = 0.375, p < .001). Gal-3 could predict patients with a moderate to high H2FPEF score using a cut-off value of 14.7, with a sensitivity of 69% and specificity of 67% (AUC: 0.702).ConclusionsGal-3 serves as an independent predictor of the H2FPEF score in the presence of DM, and the diagnostic capability of Gal-3 for Heart Failure with preserved LVEF remains unaffected by DM.
dc.identifier.doi10.1002/jcu.23559
dc.identifier.endpage1435
dc.identifier.issn0091-2751
dc.identifier.issn1097-0096
dc.identifier.issue9
dc.identifier.orcid0000-0003-1713-3451
dc.identifier.orcid0000-0001-8444-4191
dc.identifier.pmid37694561
dc.identifier.scopus2-s2.0-85170566879
dc.identifier.scopusqualityQ3
dc.identifier.startpage1429
dc.identifier.urihttps://doi.org/10.1002/jcu.23559
dc.identifier.urihttps://hdl.handle.net/11508/53792
dc.identifier.volume51
dc.identifier.wosWOS:001065538900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Clinical Ultrasound
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260511
dc.subjectHeart-Failure
dc.subjectNatriuretic Peptide
dc.subjectInhibition
dc.subjectMarker
dc.subjectMacrophages
dc.subjectPrognosis
dc.subjectFibrosis
dc.titleEffect of diabetes mellitus on association between galectin-3 and H2FPEF score in patients with unexplained dyspnea and a preserved left ventricular ejection fraction
dc.typeArticle

Dosyalar